Application Number: 10/602,456
Balschmidt et al.
Filed: June 23, 2003
Attorney Docket No.: 6460.200-US
Via Facsimile No.: 571-273-8300

AMENDMENTS TO THE CLAIMS

CLAIM LISTING

1. **(Currently amended)** A pharmaceutical composition **comprising** ~~**which comprises**~~ a peptide and **one or more isotonicity agents, wherein at least one of the isotonicity agents is** dimethyl sulfone, wherein the concentration of dimethyl sulfone is from 40 to 400 mM, wherein the peptide is selected from human growth hormone, GLP-1, GLP-2, insulin, Factor VIIa, Factor VIII, erythropoietin (EPO), glucagon, interleukin-2 (IL-2), interferon-α, and interferon-β, **an analog of the peptide, a derivative of the peptide, or derivative of the analog of the peptide** ~~**or an analogue thereof, or derivative thereof, or derivative of an analogue thereof**~~, and wherein the pharmaceutical composition is **administered parenteraly to a subject in need thereof** ~~**for parenteral administration**~~.

2. (Cancelled)

3. (Previously presented) A pharmaceutical composition according to claim 1, wherein the concentration of dimethyl sulfone is from 125 to 350 mM.

4. (Original) A pharmaceutical composition according to claim 1, wherein the composition is a solution.

5. (Original) A pharmaceutical composition according to claim 1, wherein the composition is a suspension.

6. **(Currently amended)** A pharmaceutical composition according to claim 1, ~~**which is suitable for administration**~~ **wherein the pharmaceutical composition is administered by injection or infusion to a subject in need thereof** ~~**by injection or infusion**~~.

7. **(Currently amended)** A pharmaceutical composition according to claim 6, ~~**which is suitable for**~~ **wherein the pharmaceutical composition is administered subcutaneously to a subject in need thereof** ~~**subcutaneous administration**~~.

8. **(Currently amended)** A pharmaceutical composition according to claim 6, **wherein the pharmaceutical composition is administered intramuscularly to a subject in need thereof** ~~**which is suitable for intramuscular administration**~~.

9. **(Currently amended)** A pharmaceutical composition according to claim 6, **wherein the pharmaceutical composition is administered intravenously to a subject in need thereof** ~~**which is suitable for intravenous administration**~~.

10. **(Currently amended)** A pharmaceutical composition according to claim 1, **wherein the pharmaceutical composition is administered pulmonaly to a subject in need thereof** ~~**which is suitable for pulmonal administration**~~.

11. **(Currently ameded)** A pharmaceutical composition according to claim 1, **wherein the pharmaceutical composition is administered opthalmically or topically to a subject in need thereof** ~~**which is suitable for ophthalmic administration or topical administration**~~.

12. (Cancelled)

13. (Previously presented) A pharmaceutical composition according to claim 1, wherein the peptide is selected from human insulin, a derivative of human insulin, an analogue of human insulin, or a derivative of an analogue of human insulin.

14. (Original) A pharmaceutical composition according to claim 13, wherein the peptide is human insulin.

15. (Original) A pharmaceutical composition according to claim 13, wherein the peptide is Asp(B28)-human insulin.

16. (Original) A pharmaceutical composition according to claim 13, wherein the peptide is Lys(B28) Pro(B29)-human insulin.

17. (Original) A pharmaceutical composition according to claim 13, wherein the peptide is Lys(B3) Glu(B29)-human insulin.

18. (Original) A pharmaceutical composition according to claim 13, wherein the peptide is $N^{\varepsilon B29}$-tetradecanoyl des (B30)-human insulin.

19. (Original) A pharmaceutical composition according to claim 13, wherein the peptide is Gly(A21) Arg(B31) Arg(B32)-human insulin.

20. (Previously presented) A pharmaceutical composition according to claim 13, wherein the peptide is $N^{\varepsilon B29}$–lithocholoyl-γ-glutamyl des (B30)-human insulin.

21. (Previously presented) A pharmaceutical composition according to claim 1, wherein the peptide is Gly(8)-human GLP-1.

22. (Previously presented) A pharmaceutical composition according to claim 1, wherein the peptide is Arg(34), N-ε-(γ-Glu(N-α-hexadecanoyl))-Lys(26)-human GLP-1(7-37)OH.

23. (Previously presented) A pharmaceutical composition according to claim 1, wherein the peptide is Gly(2)-human GLP-2.